Longeveron (LGVN) Stock Price, News & Analysis

Company Overview

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty. These uses remain investigational, and Lomecel-B has not been approved by the U.S. Food and Drug Administration for commercial use.

Founded in 2014 and headquartered in Miami, Florida, Longeveron conducts its development activities through clinical research programs in the United States and collaboration with medical and research institutions. The company is led by Chief Executive Officer Wa’el Hashad, who joined Longeveron after holding leadership positions in the biopharmaceutical industry.

Key Stats

• Today's Range: $2.40 to $2.90
• 50-Day Range: $1.39 to $7.33
• 52-Week Range: $1.31 to $12.30
• Volume: 60,383 shs
• Average Volume: 206,530 shs
• Market Capitalization: $7.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $80.00
• Consensus Rating: Hold

Longeveron Stock Analysis - MarketRank™

Longeveron scored higher than 34% of companies evaluated by MarketBeat, and ranked 749th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Longeveron has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Longeveron has a consensus price target of $80.00, representing about 3,000.8% upside from its current price of $2.58.

Amount of Analyst Coverage

Longeveron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Longeveron is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Longeveron is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Longeveron has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.32% of the float of Longeveron has been sold short.

Short Interest Ratio / Days to Cover

Longeveron has a short interest ratio ("days to cover") of 2.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longeveron has recently increased by 114.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Longeveron does not currently pay a dividend.

Dividend Growth

Longeveron does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

Longeveron has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Longeveron this week, compared to 3 articles on an average week.

Search Interest

21 people have searched for LGVN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Longeveron insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.42% of the stock of Longeveron is held by insiders.

Percentage Held by Institutions

10.01% of the stock of Longeveron is held by institutions.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LGVN
• CIK: 1721484
• Web: www.longeveron.com
• Phone: 305-302-7158
• Fax: N/A
• Employees: 38
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Longeveron: $80.00
• High Price Target: $80.00
• Low Price Target: $80.00
• Potential Upside/Downside: +3,138.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.70 million
• Net Margins: -1,977.59%
• Pretax Margin: -1,977.59%
• Return on Equity: -223.19%
• Return on Assets: -150.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.63
• Quick Ratio: 2.63

Sales & Book Value

• Annual Sales: $1.20 million
• Price / Sales: 6.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 1.00

Miscellaneous

• Outstanding Shares: 3,190,000
• Free Float: 2,951,000
• Market Cap: $7.88 million
• Optionable: Not Optionable
• Beta: -0.09